S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
Log in

NASDAQ:CBIO - Catalyst Biosciences Stock Price, Forecast & News

$4.97
-0.12 (-2.36 %)
(As of 12/12/2019 04:00 PM ET)
Today's Range
$4.82
Now: $4.97
$5.19
50-Day Range
$4.97
MA: $5.44
$5.89
52-Week Range
$4.52
Now: $4.97
$10.84
Volume84,828 shs
Average Volume173,272 shs
Market Capitalization$59.84 million
P/E RatioN/A
Dividend YieldN/A
Beta2.16
Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors. The company is also developing Dalcinonacog alfa, a Factor IX drug, which has completed enrollment of a Phase I/II subcutaneous dosing trial for the prophylactic treatment of individuals with hemophilia B; CB 2679d-GT, a FIX gene therapy for the treatment of hemophilia B; and CB 2782, an anti-C3 protease program for the treatment of dry age-related macular degeneration (AMD), as well as CB 1965a, a Factor Xa therapeutic program used as a universal procoagulant. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CBIO
CUSIP87611R30
Phone650-871-0761

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10,000.00
Book Value$10.04 per share

Profitability

Net Income$-30,060,000.00

Miscellaneous

Employees21
Market Cap$59.84 million
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive CBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for CBIO and its competitors with MarketBeat's FREE daily newsletter.


Catalyst Biosciences (NASDAQ:CBIO) Frequently Asked Questions

What is Catalyst Biosciences' stock symbol?

Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO."

When did Catalyst Biosciences' stock split? How did Catalyst Biosciences' stock split work?

Catalyst Biosciences's stock reverse split on Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 10th 2017. An investor that had 100 shares of Catalyst Biosciences stock prior to the reverse split would have 7 shares after the split.

How were Catalyst Biosciences' earnings last quarter?

Catalyst Biosciences Inc (NASDAQ:CBIO) posted its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($1.06) EPS for the quarter, topping analysts' consensus estimates of ($1.07) by $0.01. View Catalyst Biosciences' Earnings History.

When is Catalyst Biosciences' next earnings date?

Catalyst Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Catalyst Biosciences.

What price target have analysts set for CBIO?

3 brokerages have issued 1-year price targets for Catalyst Biosciences' shares. Their forecasts range from $24.00 to $25.00. On average, they anticipate Catalyst Biosciences' stock price to reach $24.33 in the next year. This suggests a possible upside of 389.6% from the stock's current price. View Analyst Price Targets for Catalyst Biosciences.

What is the consensus analysts' recommendation for Catalyst Biosciences?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Biosciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalyst Biosciences.

Has Catalyst Biosciences been receiving favorable news coverage?

Media coverage about CBIO stock has been trending extremely negative on Thursday, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Catalyst Biosciences earned a coverage optimism score of -4.0 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an impact on the company's share price in the next several days. View News Stories for Catalyst Biosciences.

Are investors shorting Catalyst Biosciences?

Catalyst Biosciences saw a increase in short interest in October. As of October 31st, there was short interest totalling 301,400 shares, an increase of 10.0% from the September 30th total of 273,900 shares. Based on an average trading volume of 119,200 shares, the days-to-cover ratio is presently 2.5 days. Approximately 2.7% of the company's shares are sold short. View Catalyst Biosciences' Current Options Chain.

Who are some of Catalyst Biosciences' key competitors?

What other stocks do shareholders of Catalyst Biosciences own?

Who are Catalyst Biosciences' key executives?

Catalyst Biosciences' management team includes the folowing people:
  • Dr. Nassim Usman, Pres, CEO & Director (Age 59)
  • Mr. Fletcher Payne, Chief Financial Officer (Age 56)
  • Dr. Howard Levy, Chief Medical Officer (Age 65)
  • Dr. Charles S. Craik, Co-Founder & Chairman of Scientific Advisory Board
  • Mr. Andrew Hetherington M.B.A., Sr. VP of Technical Operations

Who are Catalyst Biosciences' major shareholders?

Catalyst Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include Millennium Management LLC (5.84%) and Wedbush Securities Inc. (0.17%). Company insiders that own Catalyst Biosciences stock include Howard Levy, James E Flynn and John P Richard. View Institutional Ownership Trends for Catalyst Biosciences.

Which major investors are buying Catalyst Biosciences stock?

CBIO stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC and Wedbush Securities Inc.. View Insider Buying and Selling for Catalyst Biosciences.

How do I buy shares of Catalyst Biosciences?

Shares of CBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Catalyst Biosciences' stock price today?

One share of CBIO stock can currently be purchased for approximately $4.97.

How big of a company is Catalyst Biosciences?

Catalyst Biosciences has a market capitalization of $59.84 million and generates $10,000.00 in revenue each year. The biopharmaceutical company earns $-30,060,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Catalyst Biosciences employs 21 workers across the globe.View Additional Information About Catalyst Biosciences.

What is Catalyst Biosciences' official website?

The official website for Catalyst Biosciences is http://www.catalystbiosciences.com/.

How can I contact Catalyst Biosciences?

Catalyst Biosciences' mailing address is 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-871-0761 or via email at [email protected]


MarketBeat Community Rating for Catalyst Biosciences (NASDAQ CBIO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  242 (Vote Outperform)
Underperform Votes:  237 (Vote Underperform)
Total Votes:  479
MarketBeat's community ratings are surveys of what our community members think about Catalyst Biosciences and other stocks. Vote "Outperform" if you believe CBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2019 by MarketBeat.com Staff

Featured Article: Derivative

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel